

◎原 著

## Effects of $\alpha$ -linolenic acid-rich supplementation on leukotriene generation by leucocytes in patients with asthma associated with lipometabolism

Makoto Okamoto, Fumihiro Mitsunobu, Kozo Ashida, Yasuhiro Hosaki, Hirofumi Tsugeno, Norikazu Nishida, Tadashi Yokoi, Shingo Takata, Yoshiro Tanizaki, and Mitsune Tanimoto<sup>1)</sup>

Department of Medicine, Misasa Medical Branch, and  
<sup>1)</sup>Second Department of Medicine, Okayama University  
Medical School, Tottori, Japan

**Abstract :** Dietary sources of  $\alpha$ -linolenic acid, such as perilla seed oil, may have the capacity to inhibit the generation of leukotrienes (LTs) by leucocytes in patients with asthma, as has been reported with the consumption of other long-chain n-3 fatty acids.

The factors affecting the suppression of leukotriene (LT) C<sub>4</sub> generation by leucocytes were examined by comparing the clinical features of patients with asthma who had been given dietary perilla seed oil (n-3 fatty acids). Group A consisted of patients in whom the leucocyte generation of dietary perilla seed oil LTC<sub>4</sub> was suppressed by this procedure. Group B consisted of those in whom LTC<sub>4</sub> generation was not suppressed.

LTC<sub>4</sub> generation by leucocytes significantly decreased in group A for two ( $P < 0.05$ ) and four weeks ( $P < 0.05$ ), conversely, significantly increased in group B for four weeks ( $P < 0.05$ ). The two study groups differed significantly in LTC<sub>4</sub> generation by leucocytes after four weeks of dietary supplementation ( $P < 0.05$ ). Ventilatory parameters such as peak expiratory flow (PEF), forced vital capacity (FVC) and forced expiratory volume in one second (FEV<sub>1.0</sub>) increased significantly after four weeks of dietary supplementation in group A ( $P < 0.05$ ). Values of PEF, FVC, FEV<sub>1.0</sub> and V<sub>25</sub> between groups A and B significantly differed prior to dietary supplementation. Serum levels of total cholesterol, LDL-cholesterol and phospholipid were significantly decreased by dietary supplementation in group A after four weeks. Serum levels of total-cholesterol, triglyceride, HDL-Cholesterol, LDL-Cholesterol and phospholipid values between the two study groups differed significantly prior to dietary supplementation. Serum levels of triglyceride and LDL-cholesterol differed significantly between the two

study groups after four weeks of dietary supplementation.

The effects of dietary supplementation with perilla seed oil to patients with asthma by suppressing the generation of LTC<sub>4</sub> is associated with clinical features such as respiratory function and lipometabolism.

**key word :**  $\alpha$ -linolenic acid, leukotrieneC<sub>4</sub>, bronchial asthma, lipometabolism

## Introduction

Asthma is a chronic inflammatory disease of the airways, that is characterized by recurrent episodes of wheezing, breathlessness, chest tightness, cough variable airflow obstruction (often reversible either spontaneously or with treatment) and bronchial hyperresponsiveness<sup>1)</sup>. The airways of patients with asthma have increased numbers of both inflammatory cells and their products compared with normal individuals<sup>2)</sup>. Airflow obstruction associated with asthma consists of airway wall swelling, elevated luminal secretion, increased presence of inflammatory cells in the airway wall, and muscle contraction<sup>3)</sup>. Numerous chemical mediators including leukotrienes (LTs) released in the airways can elicit an allergic reaction. Four series LTs (LTC<sub>4</sub>, LTD<sub>4</sub> and LTE<sub>4</sub>) increase postcapillary permeability, and are potent stimulators of airway smooth muscle cells that mediate airway inflammation through their involvement in vasoconstriction and mucus secretion<sup>4)</sup>. LTC<sub>4</sub> and D<sub>4</sub> can stimulate the contraction of smaller airways of pulmonary parenchymal tissue<sup>5)</sup> and the smooth muscle of the lobar and segmental bronchi *in vitro*<sup>4)</sup>. Leukotrienes are present in the blood, bronchial alveolar lavage fluid and urine of asthmatics and are produced by cells that mediate airway inflammation in asthma<sup>6)</sup>. The principal 5-lipoxygenase product of human eosinophils<sup>7)</sup> and mast cells<sup>8)</sup> is LTC<sub>4</sub>.

Our previous studies demonstrated that

histamines and LTC<sub>4</sub> participate in the onset mechanism of atopic asthma, whereas only LTC<sub>4</sub> participates in the onset of non-atopic asthma<sup>9)</sup>. Leukotrienes are generated from arachidonic acid (AA), which is released from membrane phospholipids during cell activation through the 5-lipoxygenase pathway<sup>10)</sup>. Leukotrienes B<sub>4</sub> and C<sub>4</sub> are generated from AA derived from linoleic acid (LA) (n-6 fatty acid), and LTB<sub>5</sub> and LTC<sub>5</sub> are generated from eicosapentaenoic acid (EPA) derived from  $\alpha$ -linolenic acid ( $\alpha$ -LNA) (n-3 fatty acid) through in the same 5-lipoxygenase pathway.

Polyunsaturated fatty acids (PUFA) of the n-3 series (EPA and docosahexaenoic acid-DHA) suppress the production of LTs by antagonistic metabolism, which occurs at the level of LT hydrolase through the 5-lipoxygenase pathway. At this level, PUFA may exert an effect by altering LT generation by leucocytes. Anti-inflammatory effects of PUFA have been demonstrated in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and chronic inflammatory bowel disease<sup>11-16)</sup>. Several studies have suggested beneficial effects of EPA or fish oil on asthma<sup>18-22)</sup>, whereas others have demonstrated no such effects<sup>23,24)</sup>.

Our previous studies showed that dietary supplementation with perilla seed oil, a vegetable oil rich in  $\alpha$ -LNA, inhibits the generation of LTs by leucocytes<sup>25)</sup>. In the present study, we examined the factors that affect the suppressive effects of perilla seed oil supplementation on the generation of LTC<sub>4</sub> by leucocytes in patients

with asthma.

### Subjects and Methods

Twenty six patients (16 females and 10 males) with mild asthma were admitted to our hospital for treatment (mean age, 61.0 year; range 30-84 year). Their mean serum IgE level at admission was 771.6U/ml (range 21.1 to 9780U/ml). Thirteen patients were atopic and thirteen patients were non-atopic, and the mean duration of asthma for both groups was 8.7 years.

Asthma was evaluated according to the criteria of the International Consensus of Diagnosis and Management of Asthma<sup>26</sup>. All patients demonstrated a reversible airway response, as indicated by a 15% or greater increase in forced expiratory volume in one second (FEV<sub>1.0</sub>) after inhaled bronchodilator use. The study was approved by the Institutional Human Investigation Committee at our hospital. Informed consent to participate in the study was obtained from all patients. At the time of the study, all patients were undergoing regular treatment with long-acting oral theophylline, inhaled  $\beta_2$  adrenergic agonists and glucocorticosteroid (beclomethasone dipropionate: BDP). The mean dose of inhaled BDP was 305.8  $\mu$ g/day.

The patients consumed 10-20g of perilla seed oil (rich in  $\alpha$ -LNA) per day as salad dressing and/or mayonnaise instead of other oils for 4 weeks. The mean dose of consumed perilla seed oil was 14.65 $\pm$ 1.41g/day. Other dietary components were not changed, and the amount of oil used in the diet and supplemented diet was recorded throughout the study period.

Peak expiratory flow (PEF) during the early morning and evening was recorded using a peak-flow meter (Assess: Health Scan Products Inc., Cedar Grove, NJ, USA).

The patients were classified according to the

degree of suppression of generation of LTC<sub>4</sub> by leucocytes after four weeks of dietary supplementation with perilla seed oil. Patients in whom LTC<sub>4</sub> generation was suppressed by supplementation were classified as "Diet Inhibition" (group A), and those in whom no suppression was evident, were classified as "No Inhibition" (group B).

Group A included 11 females and 4 males with a mean age of 64.3 years (range 44 to 84 years). Group B included 5 females and 6 males with a mean age of 56.5 years (range 30 to 73 years).

The concentrations of serum total cholesterol, triglyceride, high density lipoprotein (HDL)-cholesterol and phospholipid were assayed using an enzymatic method<sup>27-30</sup>. Low density lipoprotein (LDL)-cholesterol concentration was calculated from the following formula: [(serum total cholesterol) - (HDL-cholesterol) - 0.2 $\times$ (triglyceride)] (Friedwald's convert)<sup>31</sup>, and  $\beta$ -lipoprotein was assayed by turbidimetry. Serum IgE levels were estimated by the radioimmunosorbent test (RIST).

Pulmonary function tests, forced vital capacity (FVC), forced expiratory volume in one second (FEV<sub>1.0</sub>) and V<sub>25</sub> were performed using a Chestac 33 (Chest Co. Tokyo, Japan) linked to a computer while the patients were at an attack-free state.

The generation of LTC<sub>4</sub> by peripheral leucocytes was assessed as described<sup>19,32</sup>. Cells were separated by counterflow centrifugation elutriation using a JE 6B rotor (Beckman Co., Geneva, Switzerland) [33], as described<sup>32,34</sup>. The number of cells was then adjusted to 5 $\times$ 10<sup>6</sup>/ml in Tris ACM (composition: 1ml of 0.1mol/1Ca<sup>2+</sup>, 0.5 ml of 0.1mol/1Mg<sup>2+</sup> and 98.5ml Tris A buffer; Trizma preset crystal, pH 7.7; Sigma Chemical Co., St. Louis, Mo, USA). The Ca ionophore A23187 (1  $\mu$ g) was added to the cell suspension and incubated for 15 min at 37°C. Leukotriene

C4 was quantified by HPLC as described by Lam et al<sup>35</sup>. Leukotrienes were extracted using a C18 Seppak (Waters Associates, Milford, MA) and the LTC4 concentrations were determined by HPLC, Model 510 (Waters Associates, Milford, MA), equipped with an ultraviolet detector. The column was a 5mm $\times$ 10cm Radial-Pax cartridge (Shimazu Co., Kyoto, Japan). The results are expressed as ng/5 $\times$ 10<sup>6</sup> cells.

All data are expressed as means  $\pm$  SEM. Student's t-test was used for paired analysis. Groups were compared by the one-way analysis of variance (ANOVA) and  $p < 0.05$  was considered significant. Analyses were performed using Stat-View 5.0 (Abacus Concepts, Inc., Berkeley, CA).

## Results

Group A leucocytes generated significantly less LTC4 after two and four weeks of supplementation with perilla seed oil ( $P < 0.05$ ). However, LTC4 generation increased significantly after four weeks of dietary supplementation in group B ( $P < 0.05$ ). Leukotriene C4 levels significantly differed between the two study groups after four weeks of dietary supplementation ( $P < 0.05$ ) (Fig. 1).




Figure 1. Changes in LTC4 generation in two study groups. LTC4 generation decreased significantly after two and four weeks of perilla seed oil supplementation in group A (●—●). In contrast, LTC4 generation increased significantly after four weeks of supplementation in group B (●---●). Levels of LTC4 significantly differed between groups A and B after four weeks of dietary supplementation. Each point represents the mean  $\pm$  SEM for 15 subjects (group A) and 11 subjects (group B).

a, b, c and d,  $P < 0.05$ . LTC4: leukotriene C4.

Morning PEF values were significantly lower in group A than in group B during the study period ( $P < 0.05$ ). These values increased significantly in both groups after two ( $P < 0.05$ ) and four weeks ( $P < 0.05$ ) of dietary supplementation (Table 1).

Table 1. Comparison of morning PEF values between groups A and B.

	PEF value (L/min)		
	before	after two weeks	after four weeks
Group A	241.3 $\pm$ 134.9 <sup>a,b,f</sup>	259.3 $\pm$ 113.9 <sup>a,b,g</sup>	271.3 $\pm$ 105.1 <sup>b,h</sup>
Group B	366.7 $\pm$ 163.0 <sup>d,e,f</sup>	386.7 $\pm$ 148.6 <sup>d,g</sup>	388.9 $\pm$ 138.6 <sup>e,h</sup>

Group A: LTC4 generation suppressed by dietary supplementation with perilla seed oil. Group B: no suppression of LTC4 by supplementation. Each value represents the mean  $\pm$  SEM for 15 subjects (group A) and 11 subjects (group B). a, b, c, d, e, f, g and h,  $P < 0.05$ .

The FVC, FEV<sub>1.0</sub> and V<sub>25</sub> values were significantly lower in group A than in group B prior to dietary supplementation. The FVC and FEV<sub>1.0</sub> values increased significantly in group A following dietary supplementation ( $P < 0.05$ ). However, supplementation did not significantly increase these ventilatory parameters in group B. In contrast, FVC and FEV<sub>1.0</sub> values between the two study groups differed significantly after four weeks of dietary supplementation (Table 2).

Table 2. Comparison of ventilatory parameters between groups A and B.

		Dietary supplementation	
		before	after four weeks
FVC (L)	group A	2.31 $\pm$ 0.50 <sup>ab</sup>	2.43 $\pm$ 0.40 <sup>ac</sup>
	group B	3.39 $\pm$ 1.16 <sup>b</sup>	3.43 $\pm$ 1.30 <sup>c</sup>
FEV <sub>1.0</sub> (L)	group A	1.45 $\pm$ 0.48 <sup>de</sup>	1.68 $\pm$ 0.51 <sup>ef</sup>
	group B	2.68 $\pm$ 0.98 <sup>e</sup>	2.62 $\pm$ 1.07 <sup>f</sup>
V <sub>25</sub> (L/sec)	group A	0.43 $\pm$ 0.34 <sup>g</sup>	0.51 $\pm$ 0.47
	group B	0.97 $\pm$ 0.62 <sup>g</sup>	0.86 $\pm$ 0.61

Group A: LTC4 generation suppressed by dietary supplementation with perilla seed oil. Group B: no suppression of LTC4 by supplementation. Each value represents the mean  $\pm$  SEM for 15 subjects (group A) and 11 subjects (group B). a, b, c, d, e, f, and g,  $P < 0.05$ .

Serum levels of total-cholesterol, HDL-Chol-

esterol, LDL-Cholesterol and phospholipid were significantly higher in group A than in group B prior to dietary supplementation ( $P < 0.05$ ). The serum level of triglyceride was significantly lower in group A than in group B ( $P < 0.05$ ). Serum levels of total cholesterol, LDL-Cholesterol and phospholipid decreased significantly after four weeks of dietary supplementation in group A ( $P < 0.05$ ). The serum level of LDL-cholesterol in both groups decreased significantly after four weeks of dietary supplementation ( $P < 0.05$ ). Serum levels of triglyceride and LDL-cholesterol differed significantly between the two groups after four weeks of dietary supplementation ( $P < 0.05$ ) (Table 3).

Table 3. Comparison of lipometabolism between groups A and B.

		dietary supplementation	
		before	after four weeks
Total cholesterol(mg/dl)	group A	216.5 $\pm$ 39.5 <sup>ab</sup>	198.0 $\pm$ 45.9 <sup>a</sup>
	group B	191.0 $\pm$ 20.9 <sup>b</sup>	179.8 $\pm$ 31.8
Triglyceride(mg/dl)	group A	65.2 $\pm$ 25.8 <sup>c</sup>	62.4 $\pm$ 19.1 <sup>d</sup>
	group B	90.9 $\pm$ 41.3 <sup>c</sup>	80.6 $\pm$ 20.1 <sup>d</sup>
HDL-Cholesterol(mg/dl)	group A	70.1 $\pm$ 22.5 <sup>e</sup>	65.6 $\pm$ 22.1
	group B	54.7 $\pm$ 16.8 <sup>e</sup>	51.6 $\pm$ 26.0
LDL-Cholesterol(mg/dl)	group A	145.8 $\pm$ 36.7 <sup>fg</sup>	135.9 $\pm$ 22.2 <sup>gh</sup>
	group B	121.3 $\pm$ 15.1 <sup>gh</sup>	108.2 $\pm$ 20.0 <sup>hi</sup>
$\beta$ -Lipoprotein(mg/dl)	group A	428.6 $\pm$ 71.2	419.7 $\pm$ 76.8
	group B	410.1 $\pm$ 48.1	386.0 $\pm$ 63.0
Phospholipid(mg/dl)	group A	250.8 $\pm$ 19.2 <sup>ik</sup>	216.4 $\pm$ 35.0 <sup>l</sup>
	group B	199.5 $\pm$ 23.8 <sup>k</sup>	194.0 $\pm$ 28.9

Group A: LTC<sub>4</sub> generation was suppressed by dietary supplementation.  
 Group B: no suppression of LTC<sub>4</sub> generation by perilla seed oil.  
 Each value represents the mean  $\pm$  SEM for 15 subjects (group A) and 11 subjects (group B).  
 a, b, c, d, e, f, g, h, i, j and k,  $P < 0.05$ .

## Discussion

Leukotrienes constitute a group of major chemical mediators in asthma that play an important role in the late asthmatic reaction (LAR). Large quantities of these mediators are synthesized and/or released by inflammatory cells

during an allergic reaction. Leukotrienes C<sub>4</sub>, D<sub>4</sub> and E<sub>4</sub> are implicated in the pathogenesis of allergen-induced airway responsiveness as potent contractile agonists of airway smooth muscle that act by mediating the late stage of immediate airway obstruction (fall in FEV<sub>1.0</sub>) after exposure to an allergen<sup>36,37</sup>.

Dietary supplementation with perilla seed oil, which is rich in  $\alpha$ -LNA, has been proposed as a means of suppressing LT<sub>4</sub> series generation by leucocytes and of increasing the generation of the LT<sub>5</sub> series through the 5-lipoxygenase pathway. Our previous study supported this notion by demonstrating a significant suppression of LTB<sub>4</sub> and LTC<sub>4</sub> generation by leucocytes following perilla seed oil supplementation<sup>25</sup>.

The effects of n-3 fatty acids such as EPA and fish oil on asthma are controversial. Some investigators have suggested beneficial effects<sup>17-22</sup>, whereas others have reported little effect<sup>23, 24</sup>. Our preliminary examinations suggested two asthmatic populations with respect to suppression of LTC<sub>4</sub> generation by the n-3 fatty acids in perilla seed oil. We therefore compared the clinical features of patients in whom LTC<sub>4</sub> generation by leucocytes was suppressed (group A) or not (group B) by perilla seed oil supplementation. Dietary supplementation with perilla seed oil for two and four weeks significantly suppressed LTC<sub>4</sub> generation by leucocytes in group A. In contrast, LTC<sub>4</sub> generation in group B increased significantly after four weeks of supplementation. These results show that patients in whom LT generation by leucocytes is suppressed, are sensitive to dietary PUFAs. The results also suggest that n-3 fatty acids were effective in these patients.

Group A had significantly lower ventilatory parameters-PEF, FVC, FEV<sub>1.0</sub> and V<sub>25</sub>-compared with group B, suggesting that group A subjects had a clinically more severe state of asthma

than group B. The FVC and FEV<sub>1.0</sub> values were significantly improved only in group A after four weeks of perilla seed oil supplementation. This indicates that LTC<sub>4</sub> affects respiratory function in group A. PEF values increased in both two groups during the study. This was thought to be caused by the other therapy (drugs and respiratory rehabilitation) accompanied with diet therapy.

Recent dietary trends in Japan include increasing consumption of saturated fatty acids and n-6 PUFAs, whereas that of low n-3 PUFAs was decreased<sup>38)</sup>. The present results showed significantly higher levels of serum total-cholesterol, HDL-Cholesterol, LDL-Cholesterol and phospholipid and a significantly lower level of serum triglyceride in group A than in group B prior to dietary supplementation, suggesting that group A patients consumed diets that were rich in n-6 fatty acids prior to the beginning of this study.

Other reports suggest that PUFA diets—including  $\alpha$ -LNA—decrease serum lipids<sup>39-40)</sup>. Some researchers have demonstrated that perilla oil supplementation decreases serum lipids in rats<sup>47,48)</sup>. In the present study, the levels of serum total cholesterol, LDL-cholesterol and phospholipid decreased significantly in group A after four weeks of perilla seed oil supplementation and the serum levels of triglyceride and LDL-cholesterol differed significantly between the two groups after four weeks of dietary supplementation. These results indicate that dietary supplementation with  $\alpha$ -LNA affects lipometabolism.

The results obtained in the present study suggest that perilla seed oil supplementation helps in treating selected patients with asthma by suppressing leukotriene generation by leucocytes. In addition, lipometabolism may be associated with this effect. The present study also indicates that dietary therapy may help attenuate asthmatic symptoms. Further studies are needed so that a nutritionally balanced therapeutic diet

can be developed for patients with asthma.

## References

1. Guidelines for the diagnosis, management of asthma: Expert Panel Report II. Bethesda, MD. National Institutes of Health NIH publication No. 97-4051, 1997.
2. Holgate S: Mediator and cytokine mechanisms in asthma. *Thorax*, 48: 103-109, 1993.
3. Kaliner M, Eggleston PA, Mathews KP: Rhinitis and asthma. *JAMA*, 258: 2851-2871, 1987.
4. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B: Leukotrienes are potent constrictors of human bronchi. *Nature*, 288: 484-486, 1980.
5. Chagnon M, Gentile J, Gladu M, Sirois P: The mechanism of action of leukotrienes A<sub>4</sub>, C<sub>4</sub> and D<sub>4</sub> on human lung parenchyma in vitro. *Lung*, 163: 55-62, 1985.
6. Henderson WR Jr: Role of leukotrienes in asthma. *Ann Allergy*, 72: 272-278, 1994; .
7. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA: Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of LTC<sub>4</sub>. *Proc Natl Acad Sci US A*, 80: 7626-7630, 1983.
8. Peters SP, MacGlashan DW, Schulman ES, et al.: Arachidonic acid metabolism in purified human lung mast cells. *J Immunol*, 132: 1972-1979, 1984.
9. Mitsunobu F, Mifune T, Hosaki Y, et al.: Different roles of histamine and leukotriene C<sub>4</sub> in the airways between patients with atopic and nonatopic asthma. *J Asthma*, 35: 67-372, 1998.
10. Thien FC, Walters EH: Eicosanoids and asthma: An update. *Prostaglandins Leukot Essent Fatty Acids*, 52: 271-288, 1995.

11. Stenson WF, Cort D, Rodgers J, et al. : Dietary supplementation with fish oil in ulcerative colitis. *Ann Intern Med*, 116 : 609-614, 1992.
12. Ikehata A, Hiwatashi N, Kinouchi Y, et al. : Effect of intravenously infused eicosapentaenoic acid on the leukotriene generation in patients with active Crohn's disease. *Am J Clin Nutr*, 56 : 938-942, 1992.
13. Lau CS, Morley KD, Belch JJ : Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis-a double-blind placebo controlled study. *Br J Rheumatol*, 32 : 982-989, 1993 ; .
14. Nielsen GL, Faarvang KL, Thomsen BS, et al. : The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis : a randomized, double blind trial. *Eur J Clin Invest*, 22 : 687-691, 1992.
15. Kojima T, Terano T, Tanabe E, Okamoto S, Tamura Y, Yoshida S : Long-term administration of highly purified eicosapentaenoic acid provides improvement of psoriasis. *Der matologica*, 182 : 225-230, 1991.
16. Mayser P, Mrowietz U, Arenberger P, et al. : Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis : results of a double-blind, randomized, placebo-controlled, multicenter trial. *J Am Acad Dermatol* , 38 : 539-547, 1998.
17. Arm JP, Horton CE, Mencia-Huerta JM, et al. : Effect of dietary supplementation with fish oil on mild asthma. *Thorax*, 43 : 84-92, 1988.
18. Arm JP, Horton CE, Spur BW, Mencia-Huerta JM, Lee TH : The effects of dietary supplementation with fish oil on the airways response to inhaled allergen in bronchial asthma. *Am Rev Respir Dis*, 39 : 1395-1400, 1989.
19. Dry J, Vincent D : Effect of a fish oil diet on asthma : Results of a 1 year double blind study. *Int Arch Allergy Appl Immunol*, 98 : 156-157, 1991.
20. Thien FC, Mencia-Huerta JM, Lee TH : Dietary fish oil effects on seasonal hay fever and asthma in pollen-sensitive subjects. *Ann Rev Respir Dis*, 147 : 1138-1143, 1993.
21. Broughton KS, Johnson CS, Pace BK, Liebman M, Kleppinger KM : Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. *Am J Clin Nutr*, 65 : 1011-1017, 1997.
22. von Schacky C, Kiefl R, Jendraschak E, Kaminski WE : n-3 fatty acids and cysteinyl-leukotriene formation in humans in vitro, ex vivo and in vivo. *J Lab Clin Med*, 121 : 302-309, 1993.
23. Picado C, Castillo JA, Schinca N, et al. : Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients : a pilot study. *Thorax*, 43 : 93-97, 1988.
24. Stenius-Aarniala B, Aro A, Hakulinen A, Ahola I, Seppala E, Vapaatalo H : Evening primrose oil and fish oil are ineffective as supplementary treatment of bronchial asthma. *Ann Allerg*, 62 : 534-537, 1989.
25. Ashida K, Mitsunobu F, Mifune T, et al. : A pilot study : Effects of dietary supplementation with  $\alpha$ -linolenic acid-enriched perilla seed oil on bronchial asthma. *Allergol Intern*, 46 : 181-185, 1997.
26. National Heart, Lung, and Blood Institutes, National Institutes of Health. Bethesda, Maryland 20982. International consensus report on diagnosis and management of asthma. *Eur Respir J*, 5 : 601-641, 1992.
27. Rautela GS, Liedtke RJ : Automated enzymic measurement of total cholesterol in serum. *Clin Chem*, 24 : 108-114, 1978.

28. Tietz NW : Textbook of Clinical Chemistry, W. B. Saunders Co., Philadelphia, PA ; ,52-53 (Techniques and procedures to minimize laboratory infections), 487-497 (Specimen collection and storage recommendations), 1986.
29. Shimazu S, Yasui K, Tani Y, Yamada H : ACTL-CoA oxidase from *Candida Tropicalis*. *Biochem Biophys Res Commun*, 91 : 108-113, 1979.
30. Takayama M, Itoh S, Nagasaki T, Tanimizu L : A new enzymatic method for determination of serum choline-containing phospholipids. *Clinica Chimica Acta*, 79 : 93-98, 1977.
31. Friedwald AT : Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. *Clin Chem*, 18 : 499-509, 1972.
32. Tanizaki Y, Kitani H, Okazaki M, Mifune T, Mitsunobu F, Kimura I : Changes in the proportions of broncho-alveolar lymphocytes, neutrophils and basophilic cells and the release of histamine and leukotrienes from bronchoalveolar cells in patients with steroid-dependent intractable asthma. *Int Arch Allergy Immunol*, 101 : 196-201, 1993.
33. Jemionek JF, Contreras TJ, French JE, Shields LJ : Technique for increased granulocyte recovery from human whole blood by counterflow centrifugation elutriation. 1. In vitro analyses. *Transfusion*, 19 : 120-128, 1979.
34. Tanizaki Y, Sudo M, Kitani H, et al. : Release of heparin-like substance and histamine from basophilic leukocytes separated by counterflow centrifugation elutriation. *Jpn J Med*, 29 : 356-361, 1990.
35. Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H : Release of leukotrienes in patients with bronchial asthma. *J Allergy Clin Immunol*, 81 : 711-717, 1988.
36. Taniguchi Y, Tamura G, Honma M, et al. : The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. *J Allergy Clin Immunol*, 92 : 507-512, 1993.
37. Hamilton AL, Watson RM, Wyile G, O'Byrne PM : Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx1005. *Thorax*, 52 : 348-354, 1997.
38. Egusa G, Murakami F, Ito C, et al. : Westernized food habits and concentrations of serum lipids in the Japanese. *Atherosclerosis* 100 : 249-255, 1993.
39. Garg ML, Cladinin MT : Alpha-linolenic acid and metabolism of cholesterol and long-chain fatty acids. *Nutrition*, 8 : 208-210, 1992.
40. Ikeda I, Mitsui K, Imaizumi K : Effect of dietary linoleic, alpha-linolenic and arachidonic acids on lipid metabolism, tissue fatty acid composition and eicosanoid production in rats. *J Sci Vitaminol*, 42 : 541-551, 1996.
41. Ikeda I, Cha JY, Yanagida T, et al. : Effects of dietary alpha linolenic, eicosapentaenoic and docosahexaenoic acids on hepatic lipogenesis and beta-oxidation in rats. *Biosci Biotechnol Biochem*, 62 : 675-680, 1998.
42. Prasad K, Mantha SV, Muir AD, Westcott ND : Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha-linolenic acid. *Atherosclerosis*, 136 : 367-375, 1998.
43. Larsson-Backstrom C, Lindmark L, Svensson L : Effects of dietary alpha-and gammalinolenic acids on liver fatty acids, lipid metabolism, and survival in sepsis. *Shock*, 4 : 11-20, 1995.
44. Koga T, Nonaka M, Gu JY, Sugano M : Linoleic and alpha-linolenic acids differently modify the effects of elaidic acid on

- polyunsaturated fatty acid metabolism and some immune indices in rats. *Br J Nutr*, 77 : 645-656, 1997.
45. Seppanen-Laakso T, Vanhanen H, Laakso I, Kohtamaki H, Viikari J : Replacement of butter on bread by rapeseed oil and rapeseed oil-containing margarine : effects on plasma fatty acid composition and serum cholesterol. *Br J Nutr*, 68 : 639-654, 1992.
46. Mensink RP, Katan MB : Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high-density lipoprotein cholesterol in healthy women and men. *N Engl J Med*, 321 : 436-441, 1989.
47. Damon M, Chavis C, Crastes de Paulet, Michel FB, Godard P : Arachidonic acid metabolism in alveolar macrophages. A comparison of cells from healthy subjects, allergic asthmatics, and chronic bronchitis patients. *Prostaglandins*, 34 : 291-309, 1987.
48. Gu JY, Wakizono Y, Dohi A, Nonaka M, Sugano M, Yamada K : Effect of dietary fats and sesamin on lipid metabolism and immune function of Sprague-Dawley rats. *Biosci Biotechnol Biochem*, 62 : 1917-1924, 1998.

### 脂質代謝に関連した気管支喘息患者における白血球ロイコトリエン産生能に対する $\alpha$ -リノレン酸食の効果

岡本 誠, 光延文裕, 芦田耕三, 保崎泰弘,  
柘野浩史, 西田典数, 横井 正, 高田真吾,  
谷崎勝朗, 谷本光音<sup>1)</sup>

岡山大学医学部附属病院三朝分院内科、

<sup>1)</sup>岡山大学医学部第二内科

エゴマ油のような $\alpha$ -リノレン酸食が他のn-3系不飽和脂肪酸食において報告されてきた様に喘息患者の白血球ロイコトリエン (LTs) 産生能を抑制すると考えられる。そこでエゴマ油 (n-3系脂肪酸) を摂取した気管支喘息患者の臨床所見を比較することによって白血球ロイコトリエン (LT) C<sub>4</sub>の抑制に影響する因子を検討した。A群はエゴマ油摂取により白血球LTC<sub>4</sub>の産生能が抑制された群であり、B群は白血球LTC<sub>4</sub>の産生能が抑制されなかった群である。A群では食事摂

取2週後 ( $P < 0.05$ ), 4週後 ( $P < 0.05$ ) に白血球LTC<sub>4</sub>産生能が低下した。逆にB群では摂取4週後有意に増加した ( $P < 0.05$ )。2群間で食事摂取4週後に白血球LTC<sub>4</sub>産生能に有意差がみられた ( $P < 0.05$ )。ピークフロー値 (PEF)、努力性肺活量 (FVC)、1秒量 ( $FEV_1$ ) といった呼吸機能はA群において食事摂取4週後に有意に上昇した ( $P < 0.05$ )。食事摂取前のPEF、FVC、 $FEV_1$ 、 $V_{25}$ はA群、B群の2群間で有意差がみられた。A群において血清総コレステロール、低比重リポ蛋白 (LDL) コレステロール、リン脂質は食事摂取4週後に有意に低下した。食事摂取前の血清総コレステロール、中性脂肪、高比重リポ蛋白コレステロール、LDLコレステロール、リン脂質において2群間に有意差がみられた。血清中性脂肪、LDLコレステロールは食事摂取4週後2群間に有意差がみられた。気管支喘息患者のある群へのエゴマ油食はLTC<sub>4</sub>産生能を抑制し、それには呼吸機能や脂質代謝といった臨床因子が関連していると考えられた。